2007
DOI: 10.1210/jc.2007-1116
|View full text |Cite
|
Sign up to set email alerts
|

Kisspeptin-54 Stimulates Gonadotropin Release Most Potently during the Preovulatory Phase of the Menstrual Cycle in Women

Abstract: Elevation of plasma kisspeptin in human females potently stimulates LH release in the preovulatory phase and provides a novel mechanism for manipulation of the HPG axis in women.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

13
220
1
6

Year Published

2013
2013
2023
2023

Publication Types

Select...
5
2
1

Relationship

2
6

Authors

Journals

citations
Cited by 254 publications
(240 citation statements)
references
References 51 publications
13
220
1
6
Order By: Relevance
“…Because kisspeptins are known as the most important activators of GnRH neurons (55) and they are able to cause a powerful stimulation in LH and FSH secretion in both humans and animal models (48,(56)(57)(58), kisspeptin administration may have potential therapeutic effects to treat infertility. The first evidence of this effect was provided by a clinical trial in which women with functional hypothalamic amenorrhea were subjected to a protocol of twice-daily sc kisspeptin-54 administration for 2 weeks.…”
Section: May Kisspeptin Be Used As a Novel Therapeutic Approach To Trmentioning
confidence: 99%
“…Because kisspeptins are known as the most important activators of GnRH neurons (55) and they are able to cause a powerful stimulation in LH and FSH secretion in both humans and animal models (48,(56)(57)(58), kisspeptin administration may have potential therapeutic effects to treat infertility. The first evidence of this effect was provided by a clinical trial in which women with functional hypothalamic amenorrhea were subjected to a protocol of twice-daily sc kisspeptin-54 administration for 2 weeks.…”
Section: May Kisspeptin Be Used As a Novel Therapeutic Approach To Trmentioning
confidence: 99%
“…KP-54 stimulated gonadotropins in healthy women and women with hypothalamic amenorrhea but long term treatment induced tachyphylaxis 122 and administration to cycling women showed a greater gonadotropin response during the pre-ovulatory phase of the menstrual cycle 90 . Post-menopausal women had a greater response to KP-10 than women in the follicular phase and women with progestogen implants while women on the combined contraceptive pill did not have a significant response 123 .…”
Section: Potential Therapeutic Applications Of Kp Analoguesmentioning
confidence: 96%
“…administration of KP-10 has similar stimulatory effects on gonadotropin secretion in men over a dose range of 0.01 to 1 μg/kg 88,89 . The stimulatory effect of KP administration to normal women is greatest during the pre-ovulatory phase of the menstrual cycle 90 .…”
Section: Introductionmentioning
confidence: 97%
“…The possible explanation for in vivo differences between the two isoforms is probably due to dissimilarities in their pharmacokinetic properties. While many studies have been done to explore the kisspeptin pharmacokinetics [99][100][101], the evidence is still not enough to understand the differences completely, although the available data is helpful to interpret the clinical studies being formed using different kisspeptin isoforms.…”
Section: Kisspeptin Pharmacokinetics In Humansmentioning
confidence: 99%
“…Inversely, markedly reduced responses were seen after Kp-10 injection or infusion in the early to mid-follicular phase, the phase in the menstrual cycle having lowest circulating oestrogen levels [100,103], although some studies also found robust LH secretion during mid-luteal phase, which was not as significant as in the preovulatory phase [63]. Similarly, potent LH and FSH responses were observed mainly during the preovulatory period in women after sustained exposure to SC Kp-54 [99]. Intriguingly, a biphasic response was observed during the mid-luteal phase after SC Kp-54, which had been observed previously after long-acting GnRH analogues [104].…”
Section: Effects Of Acute Kisspeptin Administration In Healthy Subjectsmentioning
confidence: 99%